Hepatitis C Virus Diagnosis and the Holy Grail

Infect Dis Clin N Am 32 (2018) 425–445 (2019)

It is not often the world has the opportunity to turn a public health crisis into a good news story. The development of oral, highly effective, pangenotypic direct-acting antivirals (DAAs) has now paved the way to cure the 71 million people estimated to be living with chronic hepatitis C virus (HCV) infection globally. This report highlights improving access to rapid, simple, and affordable HCV diagnostics is critical to achieve global HCV elimination.

Hepatitis C Virus Diagnosis and the Holy Grail

Hepatitis C Virus Diagnosis and the Holy Grail (215)

Website
English
In partnership with:
ISFF
FUAS
Correlation Network